Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer

References

• Peng J, Sengupta S, Jordan VC. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med. Chem.9(5), 481–499 (2009).
   PubMed Web of Science ®Google Scholar
• Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol.13(2), 513–529 (1995).
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl Cancer Inst.88(21), 1529–1542 (1996).
   PubMed Web of Science ®Google Scholar
• Ward JH. Duration of adjuvant endocrine therapy of breast cancer: how much is enough? Curr. Opin. Obstet. Gynecol.22(1), 51–55 (2010).
   PubMed Web of Science ®Google Scholar
• Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin. Breast Cancer1(Suppl. 1), S9–S14 (2000).
   PubMedGoogle Scholar
• Hiscox S, Davies EL, Barrett-Lee P. Aromatase inhibitors in breast cancer. Maturitas63(4), 275–279 (2009).
   PubMed Web of Science ®Google Scholar
• Geisler J, King N, Anker G et al.In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res.4(9), 2089–2093 (1998).
   PubMed Web of Science ®Google Scholar
• Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer74(8), 1286–1291 (1996).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Jones A, Johnston SR et al.In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin. Cancer Res.1(12), 1511–1515 (1995).
   PubMed Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol.20(3), 751–757 (2002).
   PubMed Web of Science ®Google Scholar
• Johannessen DC, Engan T, Di Salle E et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a Phase I study. Clin. Cancer Res.3(7), 1101–1108 (1997).
   PubMed Web of Science ®Google Scholar
• Tobias JS. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. Ann. Oncol.15(12), 1738–1747 (2004).
   PubMed Web of Science ®Google Scholar
• Herold CI, Blackwell KL. The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. Breast17(Suppl. 1), S15–S24 (2008).
   PubMedGoogle Scholar
• Mansell J, Monypenny IJ, Skene AI et al. The effect of quantitative oestrogen receptor expression on recurrence in postmenopausal women with early stage breast cancer. Presented at: 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 10–14 December 2008 (Abstract 1131).
   Google Scholar
• Mauriac L, Keshaviah A, Debled M et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann. Oncol.18(5), 859–867 (2007).
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet365(9453), 60–62 (2005).
   PubMed Web of Science ®Google Scholar
• Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol.9(1), 45–53 (2008).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med.361(8), 766–776 (2009).
   PubMed Web of Science ®Google Scholar
• Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol.14(10), 2738–2746 (1996).
   PubMed Web of Science ®Google Scholar
• Houghton J. Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) – data reported on behalf of the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) Trialists’ Group. Ann. Oncol.17(Suppl. 9) (2006) (Abstract 243PD).
   PubMedGoogle Scholar
• Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med.353(26), 2747–2757 (2005).
   PubMed Web of Science ®Google Scholar
• Tang SC. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials? Cancer Invest.26(5), 481–490 (2008).
   PubMed Web of Science ®Google Scholar
• Rugo HS. The importance of distant metastases in hormone-sensitive breast cancer. Breast17(Suppl. 1), S3–S8 (2008).
   PubMed Web of Science ®Google Scholar
• Jassem J. Intergroup Exemestane Study mature analysis: overall survival data. Anticancer Drugs19(Suppl. 1), S3–S7 (2008).
   PubMedGoogle Scholar
• Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet369(9561), 559–570 (2007).
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Jonat W, Hilfrich J et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J. Clin. Oncol.25(19), 2664–2670 (2007).
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol.23(22), 5138–5147 (2005).
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Jeong JH, Wickerham DL et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J. Clin. Oncol.26(12), 1965–1971 (2008).
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol.9(9), 840–849 (2008).
   PubMed Web of Science ®Google Scholar
• Rea D, Seynaeve C, Jones SE et al. Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: rhe TEAM trial, a prospective, randomized, Phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December 2009 (Abstract 11).
   Google Scholar
• Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res. Treat.105(Suppl. 1), 45–53 (2007).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Greil R, Gnant M et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J. Natl Cancer Inst.99(24), 1845–1853 (2007).
   PubMed Web of Science ®Google Scholar
• Geisler J, Lonning PE. Aromatase inhibition: translation into a successful therapeutic approach. Clin. Cancer Res.11(8), 2809–2821 (2005).
   PubMed Web of Science ®Google Scholar
• Sainsbury R. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? Br. J. Cancer90(9), 1733–1739 (2004).
   PubMed Web of Science ®Google Scholar
• Geisler J, Helle H, Ekse D et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin. Cancer Res.14(19), 6330–6335 (2008).
   PubMed Web of Science ®Google Scholar
• Lonning PE. Aromatase inhibitors in breast cancer. Endocr. Relat. Cancer11(2), 179–189 (2004).
   PubMed Web of Science ®Google Scholar
• Jones AL, Powles TJ, Law M et al. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J. Clin. Oncol.10(10), 1547–1552 (1992).
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Amoroso D et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J. Clin. Oncol.19(22), 4209–4215 (2001).
   PubMed Web of Science ®Google Scholar
• Rose C, Vtoraya O, Pluzanska A et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer39(16), 2318–2327 (2003).
   PubMed Web of Science ®Google Scholar
• Gershanovich M, Chaudri HA, Campos D et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann. Oncol.9(6), 639–645 (1998).
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer92(9), 2247–2258 (2001).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol.21(11), 2101–2109 (2003).
   PubMed Web of Science ®Google Scholar
• Smith I, Cataliotti L; on behalf of the IMPACT and PROACT Trialists. Anastrozole versus tamoxifen as neoadjuvant therapy for oestrogen receptor-positive breast cancer in postmenopausal women: the IMPACT and PROACT trials. Presented at: European Breast Cancer Conference. Hamburg, Germany, 16–20 March 2004 (Abstract 47).
   Google Scholar
• Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol.23(22), 5108–5116 (2005).
   PubMed Web of Science ®Google Scholar
• Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol.12(11), 1527–1532 (2001).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann. Oncol.18(7), 1133–1144 (2007).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol.20(8), 1319–1329 (2009).
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Lembersky B, Jeong JH et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin. Breast Cancer7(5), 416–421 (2006).
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol.28(23), 3784–3796 (2010).
   PubMed Web of Science ®Google Scholar
• Hadji P. An economic analysis of arthralgia/myalgia versus recurrence in women with hormone receptor-positive (HR+) breast cancer (BC) on aromatase inhibitors (AIs). J. Clin. Oncol.27(15 Suppl.) (2009) (Abstract e11601).
   Google Scholar
• Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol.25(5), 486–492 (2007).
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer9(8), 576–586 (2009).
   PubMed Web of Science ®Google Scholar
• Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA302(13), 1429–1436 (2009).
   PubMed Web of Science ®Google Scholar
• Gligorov J KI, Luporsi E, Namer M. Recommandations pour la pratique clinique: Nice–Saint-Paul-de-Vence 2009 « cancers du sein » et « soins de support » Partie I – Cancers du sein. Oncologie11, 497–505 (2009).
   Web of Science ®Google Scholar
• Landesberg R, Eisig S, Fennoy I, Siris E. Alternative indications for bisphosphonate therapy. J. Oral Maxillofac. Surg.67(5 Suppl.), 27–34 (2009).
   PubMed Web of Science ®Google Scholar
• Gnant M, Dubsky P, Fitzal F et al. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? Clin. Breast Cancer9(Suppl. 1), S18–S27 (2009).
   Google Scholar
• Brufsky AM, Bosserman LD, Caradonna RR et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin. Breast Cancer9(2), 77–85 (2009).
   PubMed Web of Science ®Google Scholar
• Brufsky A, Harker WG, Beck JT et al. The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up. Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December 2009 (Abstract 4083).
   Google Scholar
• Eidtmann H, DeBoer R, Llombart A et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Presented at: 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 10–14 December 2008 (Abstract 44).
   Google Scholar
• Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann. Oncol. DOI: 10.1093/annonc/mdq217 (2010) (Epub ahead of print).
   Google Scholar
• LLombarto A, Frassoldati A, Paija O et al. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. Presented at: ASCO 2009 Breast Cancer Symposium. San Francisco, CA, USA, 8–10 October 2009 (Abstract 213).
   Google Scholar
• Nogués X, Peña MJ, Martinez M et al. Bone health in postmenopausal women treated with adjuvant aromatase inhibitors for early breast cancer: 12 months follow-up. Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December 2009 (Abstract 3175).
   Google Scholar
• Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergstrom B. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann. Oncol.18(7), 1165–1171 (2007).
   PubMed Web of Science ®Google Scholar
• Stopeck A, Fujiwara Y, Lichinitser M et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases. Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December 2009 (Abstract 22).
   Google Scholar
• Winter MC, Holen I, Coleman RE. Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat. Rev.34(5), 453–475 (2008).
   PubMed Web of Science ®Google Scholar
• Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat. Rev.34(Suppl. 1), S19–S24 (2008).
   Web of Science ®Google Scholar
• Santini D, Vincenzi B, Avvisati G et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin. Cancer Res.8(5), 1080–1084 (2002).
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Galluzzo S et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res.13(15 Pt 1), 4482–4486 (2007).
   PubMed Web of Science ®Google Scholar
• Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia22(5), 941–950 (2008).
   PubMed Web of Science ®Google Scholar
• Rack BK, Genss E-M, Schoberth A et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Presented at: 30th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 13–16 December 2007 (Abstract 511).
   Google Scholar
• Aft R, Ylagan L, Chavez-MacGregor M et al. Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer. J. Clin. Oncol.26(20 Suppl.) (2008) (Abstract 1021).
   Google Scholar
• Lin AP, Scott JW, Melisko J et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J. Clin. Oncol.26(20 Suppl.) (2008) (Abstract 559).
   Google Scholar
• Solomayer E, Hirnle P, Janni W et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at: 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 10–14 December 2008 (Abstract 2048).
   Google Scholar
• Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med.360(7), 679–691 (2009).
   PubMed Web of Science ®Google Scholar
• Coleman R, de Boer R, Llombarto A et al. Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December 2009 (Abstract 4082).
   Google Scholar
• Gnant M, Blaha P, Dubsky P et al. Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy? Ther. Adv. Med. Oncol.1(3), 123–136 (2009).
   PubMedGoogle Scholar
• Gnant M, Fitzal F, Jakesz R et al. Bisphosphonates as adjuvant therapy for breast cancer. Curr. Breast Cancer Rep.1, 54–63 (2009).
   Google Scholar
• Coleman RE, Winter MC, Cameron D et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer102(7), 1099–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol.23(15), 3314–3321 (2005).
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med.356(18), 1809–1822 (2007).
   PubMed Web of Science ®Google Scholar
• Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl Cancer Inst.99(4), 322–330 (2007).
   PubMed Web of Science ®Google Scholar
• Kristensen B, Ejlertsen B, Mouridsen HT et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol.47(4), 740–746 (2008).
   PubMed Web of Science ®Google Scholar
• Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann. Oncol.19(8), 1407–1416 (2008).
   PubMed Web of Science ®Google Scholar
• Aebi S, Davidson T, Gruber G, Castiglione M. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), v9–v14 (2010).
   PubMed Web of Science ®Google Scholar